HIV -1 Infection
23
7
9
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 23 trials
100.0%
+13.4% vs benchmark
9%
2 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (23)
PERSON-CENTERED APPROACHES TO VIREMIA: CONNECTION, RAPPORT, AND ENGAGEMENT STUDY
HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study
Analyses of Newly Diagnosed HIV Infection in Hong Kong
Study of GS-0415 and How It Works in People With HIV
A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV
REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE
Study of Combined GARP:TGF-β1/PD-1 Blockade as a Shock-and-kill Strategy in HIV-1 Cure
A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV
Early Neutralizing Antibodies in Infants Living With HIV to Enhance Their Life (2)
Early Neutralizing Antibodies in Infants Living With HIV to Enhance Their Life
Impacts of HIV Treatment Regimens on Archived Drug Resistance
Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
Resistance Profile to Antiretroviral Medications in Individuals Living With HIV Who Failed a First-Line Regimen With Tenofovir / Lamivudina and Dolutegravir in Brasil
Integrating iSYV Within HIV Clinical Care for Youth Living With HIV in Tanzania
Short-term Effects of Methamphetamine on Residual Latent HIV Disease Study
A Study to Evaluate Performance, Usability, and Contrived Result Interpretation of TruPlex HIV/HepB/Syphilis Rapid Test
Safety Study of MucoCept-CVN
Combining Latency Reversing Agents to Address the HIV Reservoir
Prevention ICONA Dedicated Ensemble
Establishment of a Database of HIV Subjects Initiating or Simplifying Dual Therapy With Dolutegravir/Lamivudine